NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov. (Comparative Effectiveness Reviews, No. 76.)
The following databases have been searched for relevant information:
Database Searches: Hepatitis C: Treatment
| Name | Date Limits | Platform Provider |
|---|---|---|
| Medline | 2002 through August 2012 | OvidSP |
| Embase | 2002 through April 2012 | Embase (Elsevier) |
| Cochrane Library: CDSR, DARE, CCRCT | 2002 through August 2012 | Cochrane Library |
| Clinical Trials.gov | 2002 through August 2012 | |
| Drugs@FDA | 2002 through August 2012 | |
| Health Canada Drug Products Database | 2002 through August 2012 | |
| European Public Assessment Reports (European Medicine Agency) | 2002 through August 2012 | |
| Scopus | 2002 through August 2012 | Scopus |
| PsycINFO | 2002 through August 2012 | OvidSP |
Hand Search of Journals & Supplements - Topic-Specific Search Terms
| Concept | Controlled Vocabulary | Keywords |
|---|---|---|
| Hepatitis C | Hepatitis C/ Hepatitis C, Chronic/ Hepacivirus/OR | hcv.mp hepacivirus$.mp |
| Treatment | Antiviral agents/ Interferons/ Interferon-alpha/ Interferon Alfa-2a/ Interferon Alpha-2b/ Exp Polyethylene Glycols/ Ribavirin/ Exp Protease Inhibitors/ | Interferon$ interferon alpha-2a interferon alpha-2b IFNalpha2a IFNalpha2b interferon alpha 2a interferon alpha 2b pegasys Peg-intron peginterferon alpha-2a peginterferon alpha-2b peginterferon alpha 2a peginterferon alpha 2b pegylated interferon$ IFN$ PEG IFN$ Ribavirin RBV protease inhibitor$ polymerase inhibit$ HCV protease$ Telaprevir boceprevir |
| Harms - treatment | AE.fs MO.fs PO.fs TO.fs CT.fs AE=adverse effects CT=contraindications MO=mortality PO=poisoning TO=toxicity | Unsafe Safety harm$ complication$ poison$ risk$ side-effect$ side effect$ (undesirable ADJ1 effect$) (treatment ADJ1 emergent) tolerab$ toxic$ adrs (adverse ADJ2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)) (undesirable ADJ1 effect$) (treatment ADJ1 emergent) tolerab$ toxic$ adrs (adverse ADJ2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)) |
Original Search: 12/16/2011
Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) 1946 to November Week 3 2011,
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations December 15, 2011
| 1 | Hepatitis C/ or Hepatitis C, Chronic/ or Hepacivirus/ or Hepatitis C.mp. or hepacivirus$.mp. or HCV.mp. | 58901 |
| 2 | Antiviral agents/ or Interferons/ or Interferon-alpha/ or Interferon Alfa-2a/ or Interferon Alpha-2b/ or Interferon$.mp. or interferon alpha-2a.mp. or interferon alpha-2b.mp. or IFNalpha2a.mp. or IFNalpha2b.mp. or interferon alpha 2a.mp. or interferon alpha 2b.mp. or exp Polyethylene Glycols/ or pegasys.mp. or Peg-intron.mp. or peginterferon alpha-2a.mp. or peginterferon alpha-2b.mp. or peginterferon alpha 2a.mp. or peginterferon alpha 2b.mp. or pegylated interferon$.mp. or IFN$.mp. or PEG IFN$.mp. or Ribavirin/ or ribavirin.mp. or RBV.mp. or exp Protease Inhibitors/ or protease inhibitor$.mp. or polymerase inhibit$.mp. or HCV protease$.mp. or telaprevir.mp. or boceprevir.mp. | 379981 |
| 3 | 1 and 2 | 17670 |
| 4 | (randomized controlled trial or controlled clinical trial or meta analysis or review).pt. or clinical trials as topic/ or cohort studies/ or randomized.ab. or randomly.ab. or placebo.ab. or (systematic adj1 review).ti,ab. | 2498350 |
| 5 | 3 and 4 | 5896 |
| 6 | limit 5 to (yr="2002 -Current" and ("adult (19 to 44 years)" or "middle age (45 to 64 years)" or "all aged (65 and over)")) | 1382 |
| 7 | (unsafe or safety or harm$ or complication$ or poison$ or risk$).mp. or AE.fs. or MO.fs. or PO.fs. or TO.fs. or CT.fs. or side-effect$.mp. or (undesirable adj1 effect$).mp. or (treatment adj1 emergent).mp. or tolerab$.mp. or toxic$.mp. or adrs.mp. or (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).mp. | 3892024 |
| 8 | 1 and 2 and 7 | 7401 |
| 9 | 4 and 8 | 3168 |
| 10 | limit 9 to (yr="2002 -Current" and ("adult (19 to 44 years)" or "middle age (45 to 64 years)" or "all aged (65 and over)")) | 885 |
| 11 | Counseling/ or Sex Counseling/ or Health Education/ or Patient Education as Topic/ or Psychotherapy/ or Behavior Therapy/ or Cognitive Therapy/ or Immunization/ or Immunotherapy/ or Psychotherapy, Brief/ or Socioenvironmental Therapy/ | 268601 |
| 12 | 1 and 11 | 662 |
| 13 | 6 and (201102* or 201103* or 201104* or 201105* or 201106* or 201107* or 201108* or 201109* or 201110* or 201111* or 201112*).ed. | 132 |
| 14 | 10 and (201102* or 201103* or 201104* or 201105* or 201106* or 201107* or 201108* or 201109* or 201110* or 201111* or 201112*).ed. | 90 |
| 15 | 12 and (201102* or 201103* or 201104* or 201105* or 201106* or 201107* or 201108* or 201109* or 201110* or 201111* or 201112*).ed. | 33 |
Additional Treatment Search: 2/28/2011
Ovid MEDLINE (R) and Ovid OLDMED (R) 1947 to February Week 3 2011
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations February 28, 2011
| 1 | Hepatitis C/ or Hepatitis C, Chronic/ or Hepacivirus/ or Hepatitis C.mp. or hepacivirus$.mp. or HCV.mp. | 58837 |
| 2 | Antiviral agents/ or Interferons/ or Interferon-alpha/ or Interferon Alfa-2a/ or Interferon Alpha-2b/ or Interferon$.mp. or interferon alpha-2a.mp. or interferon alpha-2b.mp. or IFNalpha2a.mp. or IFNalpha2b.mp. or interferon alpha 2a.mp. or interferon alpha 2b.mp. or exp Polyethylene Glycols/ or pegasys.mp. or Peg-intron.mp. or peginterferon alpha-2a.mp. or peginterferon alpha-2b.mp. or peginterferon alpha 2a.mp. or peginterferon alpha 2b.mp. or pegylated interferon$.mp. or IFN$.mp. or PEG IFN$.mp. or Ribavirin/ or ribavirin.mp. or RBV.mp. or exp Protease Inhibitors/ or protease inhibitor$.mp. or polymerase inhibit$.mp. or HCV protease$.mp. or telaprevir.mp. or boceprevir.mp. | 379770 |
| 3 | 1 and 2 | 17643 |
| 4 | (randomized controlled trial or controlled clinical trial or meta analysis or review).pt. or clinical trials as topic/ or cohort studies/ or randomized.ab. or randomly.ab. or placebo.ab. or (systematic adj1 review).ti,ab. | 2497187 |
| 5 | 3 and 4 | 5889 |
| 6 | limit 5 to (yr="2002 -Current" and ("adult (19 to 44 years)" or "middle age (45 to 64 years)" or "all aged (65 and over)")) | 1380 |
| 7 | (unsafe or safety or harm$ or complication$ or poison$ or risk$).mp. or AE.fs. or MO.fs. or PO.fs. or TO.fs. or CT.fs. or side-effect$.mp. or (undesirable adj1 effect$).mp. or (treatment adj1 emergent).mp. or tolerab$.mp. or toxic$.mp. or adrs.mp. or (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).mp. | 3889277 |
| 8 | 1 and 2 and 7 | 7391 |
| 9 | 4 and 8 | 3164 |
| 10 | limit 9 to (yr="2002 -Current" and ("adult (19 to 44 years)" or "middle age (45 to 64 years)" or "all aged (65 and over)")) | 883 |
| 11 | Counseling/ or Sex Counseling/ or Health Education/ or Patient Education as Topic/ or Psychotherapy/ or Behavior Therapy/ or Cognitive Therapy/ or Immunization/ or Immunotherapy/ or Psychotherapy, Brief/ or Socioenvironmental Therapy/ | 268554 |
| 12 | 1 and 11 | 660 |
Updated Search after Peer Review: 4/04/2012
Ovid MEDLINE Search Strategy 1947 to February Week 3 2011
Searched February 28, 2011; Update Search April 04, 2012
| 1 | Hepatitis C/ or Hepatitis C, Chronic/ or Hepacivirus/ or Hepatitis C.mp. or hepacivirus$.mp. or HCV.mp. |
| 2 | Antiviral agents/ or Interferons/ or Interferon-alpha/ or Interferon Alfa-2a/ or Interferon Alpha-2b/ or Interferon$.mp. or interferon alpha-2a.mp. or interferon alpha-2b.mp. or IFNalpha2a.mp. or IFNalpha2b.mp. or interferon alpha 2a.mp. or interferon alpha 2b.mp. or exp Polyethylene Glycols/ or pegasys.mp. or Peg-intron.mp. or peginterferon alpha-2a.mp. or peginterferon alpha-2b.mp. or peginterferon alpha 2a.mp. or peginterferon alpha 2b.mp. or pegylated interferon$.mp. or IFN$.mp. or PEG IFN$.mp. or Ribavirin/ or ribavirin.mp. or RBV.mp. or exp Protease Inhibitors/ or protease inhibitor$.mp. or polymerase inhibit$.mp. or HCV protease$.mp. or telaprevir.mp. or boceprevir.mp. |
| 3 | 1 and 2 |
| 4 | (randomized controlled trial or controlled clinical trial or meta analysis or review).pt. or clinical trials as topic/ or cohort studies/ or randomized.ab. or randomly.ab. or placebo.ab. or (systematic adj1 review).ti,ab. |
| 5 | 3 and 4 |
| 6 | limit 5 to (yr="2002 -Current" and ("adult (19 to 44 years)" or "middle age (45 to 64 years)" or "all aged (65 and over)")) |
| 7 | (unsafe or safety or harm$ or complication$ or poison$ or risk$).mp. or AE.fs. or MO.fs. or PO.fs. or TO.fs. or CT.fs. or side-effect$.mp. or (undesirable adj1 effect$).mp. or (treatment adj1 emergent).mp. or tolerab$.mp. or toxic$.mp. or adrs.mp. or (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).mp. |
| 8 | 1 and 2 and 7 |
| 9 | 4 and 8 |
| 10 | limit 9 to (yr="2002 -Current" and ("adult (19 to 44 years)" or "middle age (45 to 64 years)" or "all aged (65 and over)")) |
| 11 | Counseling/ or Sex Counseling/ or Health Education/ or Patient Education as Topic/ or Psychotherapy/ or Behavior Therapy/ or Cognitive Therapy/ or Immunization/ or Immunotherapy/ or Psychotherapy, Brief/ or Socioenvironmental Therapy/ |
| 12 | 1 and 11 |
EMBASE Search Strategy 1976 – 2011
Searched April 11, 2011; Update Search April 4, 2012
| 13 | #12 AND (2002:py OR 2003:py OR 2004:py OR 2005:py OR 2006:py OR 2007:py OR 2008:py OR 2009:py OR 2010:py OR 2011:py) |
| 12 | #3 AND #11 |
| 11 | #1 AND #10 |
| 10 | 'counseling'/exp OR 'patient guidance'/exp OR 'patient counseling'/exp OR 'sexual counseling'/exp OR 'psychotherapy'/exp OR 'cognitive therapy'/exp OR 'behavior therapy'/exp OR 'sex therapy'/exp OR 'patient education'/exp OR 'immunization'/exp OR 'virus vaccine'/exp OR 'immunotherapy'/exp OR counsel* OR 'socioenvironmental therapy'/de AND [embase]/lim |
| 9 | #8 AND (2002:py OR 2003:py OR 2004:py OR 2005:py OR 2006:py OR 2007:py OR 2008:py OR 2009:py OR 2010:py OR 2011:py) |
| 8 | #3 AND #7 |
| 7 | #1 AND #2 AND #6 |
| 6 | 'adverse drug reaction'/exp OR 'adverse outcome'/exp OR 'toxicity'/exp OR 'drug toxicity'/exp OR 'drug tolerability'/exp OR 'drug safety'/exp OR 'patient safety'/exp OR unsafe OR 'safety'/exp OR harm* OR complication* OR poison* OR 'side effect'/exp OR 'side effects' OR undesirable NEAR/1 effect* OR treatment NEAR/1 emergen* OR tolerab* OR toxic* OR adrs OR adverse NEAR/2 (effect OR effects OR reaction OR reactions OR event OR events OR outcome OR outcomes) AND [embase]/lim |
| 5 | #4 AND (2002:py OR 2003:py OR 2004:py OR 2005:py OR 2006:py OR 2007:py OR 2008:py OR 2009:py OR 2010:py OR 2011:py) |
| 4 | #1 AND #2 AND #3 |
| 3 | 'cohort analysis'/exp OR 'meta analysis'/exp OR 'randomized controlled trial'/exp OR 'systematic review'/exp OR 'controlled clinical trial'/exp OR 'placebo'/exp OR 'clinical trial'/exp OR 'controlled study'/exp OR randomized.ab OR randomly.ab AND [embase]/lim |
| 2 | 'antivirus agent'/exp OR 'antivirus agent' OR 'interferon'/exp OR interferon OR 'alpha interferon'/exp OR 'alpha interferon' OR 'alpha2a interferon'/exp OR 'alpha2a interferon' OR 'alpha2b interferon'/exp OR 'alpha2b interferon' OR 'macrogol derivative'/exp OR 'macrogol derivative' OR 'peginterferon'/exp OR peginterferon OR 'peginterferon alpha2a'/exp OR 'peginterferon alpha2a' OR 'peginterferon alpha2b'/exp OR 'peginterferon alpha2b' OR 'ribavirin'/exp OR ribavirin OR 'protease inhibitor'/exp OR 'protease inhibitor' OR 'rna directed dna polymerase inhibitor'/exp OR 'rna directed dna polymerase inhibitor' OR 'rna directed rna polymerase inhibitor'/exp OR 'rna directed rna polymerase inhibitor' OR 'telaprevir'/exp OR telaprevir OR 'boceprevir'/exp OR boceprevir OR 'antiviral agent':ab,ti OR interferon*:ab,ti OR 'interferon-alpha2a':ab,ti OR 'interferon-alpha2b':ab,ti OR 'interferon alpha':ab,ti OR 'interferon alpha 2a':ab,ti OR 'interferon alpha 2b':ab,ti OR 'polyethylene glycols':ab,ti OR pegasys:ab,ti OR 'peg intron':ab,ti OR 'peginterferon alpha':ab,ti OR 'peginterferon alpha 2a':ab,ti OR 'peginterferon alpha 2b':ab,ti OR 'pegylated interferon':ab,ti OR ifn:ab,ti OR 'peg ifn':ab,ti OR 'peg ifns':ab,ti OR ribavirin:ab,ti OR rbv:ab,ti OR 'protease inhibitor':ab,ti OR 'protease inhibitors':ab,ti OR 'polymerase inhibitor':ab,ti OR 'polymerase inhibitors':ab,ti OR 'hcv protease':ab,ti OR telaprevir:ab,ti OR boceprevir:ab,ti AND [embase]/lim |
| 1 | 'hepatitis c virus':de OR 'hepatitis c':de OR 'chronic active hepatitis':de OR 'hepatitis non a non b':de AND [embase]/lim |
Cochrane Library:
Cochrane Database of Systematic Reviews & Database of Abstracts of Reviews of Effects 2002–2011
Searched April 11, 2011, Update Search April 4, 2012
| “Hepatitis C” OR Hepacivirus OR HCV (Title, Abstract, Keyword) |
| Limit to reviews, published 2002–2011 |
Cochrane Library:
Cochrane Central Register of Controlled Trials 2002–2011
Searched April 11, 2011; Update Search April 04, 2012
| "Interferon-alpha" OR "Interferon Alfa-2a" OR "Interferon Alpha-2b" OR "IFNalpha2a" OR "IFNalpha2b" OR "Interferon alpha 2a" OR "interferon alpha 2b" OR "Polyethylene Glycol*" OR pegasys OR Peg-intron OR "peginterferon alpha-2a" OR "peginterferon alpha-2b" OR "peginterferon alpha 2a" OR "peginterferon alpha 2b" OR "pegylated interferon*" OR IFN* OR "PEG IFN*" OR Ribavirin OR RBV OR "protease inhibitor*" OR "polymerase inhibit*" OR "HCV protease*" OR telaprevir OR boceprevir (Title, Abstract, Keyword) |
SCOPUS Search Strategy 1960–2011
Searched April 11, 2011; Update Search April 04, 2012
| 11 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) AND (TITLE-ABS-KEY(counseling OR “health education” OR “patient education” OR psychotherapy OR “behavior therapy” OR “cognitive therapy” OR immuniz* OR immunotherapy OR “socioenvironmental therapy” OR “cognitive behavior* therapy” OR vaccine*)) |
| 10 | TITLE-ABS-KEY(counseling OR “health education” OR “patient education” OR psychotherapy OR “behavior therapy” OR “cognitive therapy” OR immuniz* OR immunotherapy OR “socioenvironmental therapy” OR “cognitive behavior* therapy” OR vaccine*) |
| 9 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) AND (TITLE-ABS-KEY(unsafe OR safety OR harm* OR complication* OR poison* OR risk* OR side-effect* OR “side effect*” OR “undesirable effect* OR “treatment emergent” OR tolerab* OR toxic* OR “adverse effect*” OR “adverse reaction*” OR “adverse event*” OR “adverse outcome*”)) AND (LIMIT-TO(PUBYEAR, 2011) OR LIMIT-TO(PUBYEAR, 2010) OR LIMIT-TO(PUBYEAR, 2009) OR LIMIT-TO(PUBYEAR, 2008) OR LIMIT-TO(PUBYEAR, 2007) OR LIMIT-TO(PUBYEAR, 2006) OR LIMIT-TO(PUBYEAR, 2005) OR LIMIT-TO(PUBYEAR, 2004) OR LIMIT-TO(PUBYEAR, 2003)) |
| 8 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) AND (TITLE-ABS-KEY(unsafe OR safety OR harm* OR complication* OR poison* OR risk* OR side-effect* OR “side effect*” OR “undesirable effect* OR “treatment emergent” OR tolerab* OR toxic* OR “adverse effect*” OR “adverse reaction*” OR “adverse event*” OR “adverse outcome*”)) |
| 7 | TITLE-ABS-KEY(unsafe OR safety OR harm* OR complication* OR poison* OR risk* OR side-effect* OR “side effect*” OR “undesirable effect* OR “treatment emergent” OR tolerab* OR toxic* OR “adverse effect*” OR “adverse reaction*” OR “adverse event*” OR “adverse outcome*”) |
| 6 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) AND (LIMIT-TO(PUBYEAR, 2011) OR LIMIT-TO(PUBYEAR, 2010) OR LIMIT-TO(PUBYEAR, 2009) OR LIMIT-TO(PUBYEAR, 2008) OR LIMIT-TO(PUBYEAR, 2007) OR LIMIT-TO(PUBYEAR, 2006) OR LIMIT-TO(PUBYEAR, 2005) OR LIMIT-TO(PUBYEAR, 2004) OR LIMIT-TO(PUBYEAR, 2003) OR LIMIT-TO(PUBYEAR, 2002)) |
| 5 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) |
| 4 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) |
| 3 | TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly) |
| 2 | (TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telaprevir)) |
| 1 | TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv) |
OvidSP PSYCINFO Search Strategy 1806 to February Week 4 2011
Searched April 12, 2011; Update Search April 4, 2012
| 1 | hepatitis/ or (Hepatitis C or hepacivirus$ or HCV).mp. |
| 2 | [exp treatment/ or exp intervention/ or exp psychotherapy/ or exp alcohol rehabilitation/ or exp counseling/ or exp support groups/ or exp rehabilitation/ or exp mental health services/ or exp community services/ or exp outreach programs/ or exp drug rehabilitation/ or exp sobriety/ or exp detoxification/ or exp drug rehabilitation/ or exp treatment outcomes/ or exp alcoholics anonymous/] |
| 3 | alcohol*.mp. |
| 4 | 1 and 2 and 3 |
Clinicaltrials.gov
Searched April 12, 2011; Update Search April 4, 2012
| interferon alfa OR peginterferon OR ribavirin OR telaprevir OR boceprevir | Closed Studies | Studies With Results | hepatitis c | Adult, Senior |
Updated Search: 8/28/2012
Ovid MEDLINE Search Strategy 1947 to February Week 3 2011
Searched February 28, 2011; Update Search April 04, 2012; Update Search August 28, 2012
| 1 | Hepatitis C/ or Hepatitis C, Chronic/ or Hepacivirus/ or Hepatitis C.mp. or hepacivirus$.mp. or HCV.mp. |
| 2 | Antiviral agents/ or Interferons/ or Interferon-alpha/ or Interferon Alfa-2a/ or Interferon Alpha-2b/ or Interferon$.mp. or interferon alpha-2a.mp. or interferon alpha-2b.mp. or IFNalpha2a.mp. or IFNalpha2b.mp. or interferon alpha 2a.mp. or interferon alpha 2b.mp. or exp Polyethylene Glycols/ or pegasys.mp. or Peg-intron.mp. or peginterferon alpha-2a.mp. or peginterferon alpha-2b.mp. or peginterferon alpha 2a.mp. or peginterferon alpha 2b.mp. or pegylated interferon$.mp. or IFN$.mp. or PEG IFN$.mp. or Ribavirin/ or ribavirin.mp. or RBV.mp. or exp Protease Inhibitors/ or protease inhibitor$.mp. or polymerase inhibit$.mp. or HCV protease$.mp. or telaprevir.mp. or boceprevir.mp. |
| 3 | 1 and 2 |
| 4 | (randomized controlled trial or controlled clinical trial or meta analysis or review).pt. or clinical trials as topic/ or cohort studies/ or randomized.ab. or randomly.ab. or placebo.ab. or (systematic adj1 review).ti,ab. |
| 5 | 3 and 4 |
| 6 | limit 5 to (yr="2002 -Current" and ("adult (19 to 44 years)" or "middle age (45 to 64 years)" or "all aged (65 and over)")) |
| 7 | (unsafe or safety or harm$ or complication$ or poison$ or risk$).mp. or AE.fs. or MO.fs. or PO.fs. or TO.fs. or CT.fs. or side-effect$.mp. or (undesirable adj1 effect$).mp. or (treatment adj1 emergent).mp. or tolerab$.mp. or toxic$.mp. or adrs.mp. or (adverse adj2 (effect or effects or reaction or reactions or event or events or outcome or outcomes)).mp. |
| 8 | 1 and 2 and 7 |
| 9 | 4 and 8 |
| 10 | limit 9 to (yr="2002 -Current" and ("adult (19 to 44 years)" or "middle age (45 to 64 years)" or "all aged (65 and over)")) |
| 11 | Counseling/ or Sex Counseling/ or Health Education/ or Patient Education as Topic/ or Psychotherapy/ or Behavior Therapy/ or Cognitive Therapy/ or Immunization/ or Immunotherapy/ or Psychotherapy, Brief/ or Socioenvironmental Therapy/ |
| 12 | 1 and 11 |
EMBASE Search Strategy 1976 – 2011
An updated search for August 28, 2012 was not conducted as Oregon Health and Sciences University no longer subscribes to this database. |
Cochrane Library:
Cochrane Database of Systematic Reviews & Database of Abstracts of Reviews of Effects 2002–2011
Searched April 11, 2011, Update Search April 4, 2012; Update Search August 28, 2012
| “Hepatitis C” OR Hepacivirus OR HCV (Title, Abstract, Keyword) |
| Limit to reviews, published 2002–2011 |
Cochrane Library:
Cochrane Central Register of Controlled Trials 2002–2011
Searched April 11, 2011; Update Search April 04, 2012; Update Search August 28, 2012
| "Interferon-alpha" OR "Interferon Alfa-2a" OR "Interferon Alpha-2b" OR "IFNalpha2a" OR "IFNalpha2b" OR "Interferon alpha 2a" OR "interferon alpha 2b" OR "Polyethylene Glycol*" OR pegasys OR Peg-intron OR "peginterferon alpha-2a" OR "peginterferon alpha-2b" OR "peginterferon alpha 2a" OR "peginterferon alpha 2b" OR "pegylated interferon*" OR IFN* OR "PEG IFN*" OR Ribavirin OR RBV OR "protease inhibitor*" OR "polymerase inhibit*" OR "HCV protease*" OR telaprevir OR boceprevir (Title, Abstract, Keyword) |
SCOPUS Search Strategy 1960–2011
Searched April 11, 2011; Update Search April 04, 2012; Update Search August 28, 2012
| 11 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) AND (TITLE-ABS-KEY(counseling OR “health education” OR “patient education” OR psychotherapy OR “behavior therapy” OR “cognitive therapy” OR immuniz* OR immunotherapy OR “socioenvironmental therapy” OR “cognitive behavior* therapy” OR vaccine*)) |
| 10 | TITLE-ABS-KEY(counseling OR “health education” OR “patient education” OR psychotherapy OR “behavior therapy” OR “cognitive therapy” OR immuniz* OR immunotherapy OR “socioenvironmental therapy” OR “cognitive behavior* therapy” OR vaccine*) |
| 9 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) AND (TITLE-ABS-KEY(unsafe OR safety OR harm* OR complication* OR poison* OR risk* OR side-effect* OR “side effect*” OR “undesirable effect* OR “treatment emergent” OR tolerab* OR toxic* OR “adverse effect*” OR “adverse reaction*” OR “adverse event*” OR “adverse outcome*”)) AND (LIMIT-TO(PUBYEAR, 2011) OR LIMIT-TO(PUBYEAR, 2010) OR LIMIT-TO(PUBYEAR, 2009) OR LIMIT-TO(PUBYEAR, 2008) OR LIMIT-TO(PUBYEAR, 2007) OR LIMIT-TO(PUBYEAR, 2006) OR LIMIT-TO(PUBYEAR, 2005) OR LIMIT-TO(PUBYEAR, 2004) OR LIMIT-TO(PUBYEAR, 2003)) |
| 8 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) AND (TITLE-ABS-KEY(unsafe OR safety OR harm* OR complication* OR poison* OR risk* OR side-effect* OR “side effect*” OR “undesirable effect* OR “treatment emergent” OR tolerab* OR toxic* OR “adverse effect*” OR “adverse reaction*” OR “adverse event*” OR “adverse outcome*”)) |
| 7 | TITLE-ABS-KEY(unsafe OR safety OR harm* OR complication* OR poison* OR risk* OR side-effect* OR “side effect*” OR “undesirable effect* OR “treatment emergent” OR tolerab* OR toxic* OR “adverse effect*” OR “adverse reaction*” OR “adverse event*” OR “adverse outcome*”) |
| 6 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) AND (LIMIT-TO(PUBYEAR, 2011) OR LIMIT-TO(PUBYEAR, 2010) OR LIMIT-TO(PUBYEAR, 2009) OR LIMIT-TO(PUBYEAR, 2008) OR LIMIT-TO(PUBYEAR, 2007) OR LIMIT-TO(PUBYEAR, 2006) OR LIMIT-TO(PUBYEAR, 2005) OR LIMIT-TO(PUBYEAR, 2004) OR LIMIT-TO(PUBYEAR, 2003) OR LIMIT-TO(PUBYEAR, 2002)) |
| 5 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) |
| 4 | (TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv)) AND ((TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telapr))) AND (TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly)) |
| 3 | TITLE-ABS-KEY(cohort* OR "meta analysis" OR "randomized controlled trial*" OR "systematic review*" OR "controlled clinical trial*" OR "placebo" OR "clinical trial*" OR randomized OR randomly) |
| 2 | (TITLE-ABS-KEY(“antiviral agent*” OR interferon* OR interferon-alpha OR “interferon alfa-2a” OR “interferon alpha-2b” OR ifnalpha2a OR ifnalpha2b OR “interferon alpha 2a” OR “interferon alpha 2b” OR “polyethylene glycols” OR pegasys OR peg-intron) OR TITLE-ABS-KEY(“peginterferon alpha-2a” OR “peginterferon alpha-2b” OR “peginterferon alpha 2a” OR “peginterferon alpha 2b” OR “pegylated interferon*” OR ifn* OR peg ifn* OR ribavirin OR rbv OR “protease inhibitor*” OR “polymerase inhibitor*” OR “hcv protease*” OR telaprevir)) |
| 1 | TITLE-ABS-KEY(“hepatitis c” OR hepacivirus OR hcv) |
OvidSP PSYCINFO Search Strategy 1806 to February Week 4 2011
Searched April 12, 2011; Update Search April 4, 2012; Update Search August 28, 2012
| 1 | hepatitis/ or (Hepatitis C or hepacivirus$ or HCV).mp. |
| 2 | [exp treatment/ or exp intervention/ or exp psychotherapy/ or exp alcohol rehabilitation/ or exp counseling/ or exp support groups/ or exp rehabilitation/ or exp mental health services/ or exp community services/ or exp outreach programs/ or exp drug rehabilitation/ or exp sobriety/ or exp detoxification/ or exp drug rehabilitation/ or exp treatment outcomes/ or exp alcoholics anonymous/] |
| 3 | alcohol*.mp. |
| 4 | 1 and 2 and 3 |
Clinicaltrials.gov
Searched April 12, 2011; Update Search April 4, 2012, Update Search August 28, 2012
| interferon alfa OR peginterferon OR ribavirin OR telaprevir OR boceprevir | Closed Studies | Studies With Results | hepatitis c | Adult, Senior |
- Exact Search Strategy - Treatment for Hepatitis C Virus Infection in AdultsExact Search Strategy - Treatment for Hepatitis C Virus Infection in Adults
Your browsing activity is empty.
Activity recording is turned off.
See more...